



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/811,384	12/20/2000	Martin M. Bednar	P1729C1

CONFIRMATION NO. 9289

09157
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CA 94080

FORMALITIES LETTER



OC000000005950094

Date Mailed: 04/09/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825 (b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance

06/20/2001 MYUSUF1 00000014 070630 09811384

01 FC:105

130.00 CH



For questions regarding compliance to these requirements, please contact:

- A copy of this notice MUST be returned with the reply.*

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

[illegible]



Patent Docket P1729C1

SECTION

20:24pm

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Martin Bednar et al. Serial No.: 09/811,384 Filed: 20 December 2000 For: Co-administration of a Thrombolytic and an anti-CD18 Antibody	Group Art Unit: Not Yet Assigned Examiner: not assigned CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on June 11, 2001 <i>[Signature]</i> Yvonne Carter
---	--

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

BOX MISSING PART

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This is responsive to the Notice to File Missing Parts - Filing Date Granted dated . Transmitted herewith are the following documents:

1. Copy of PTO-1533
2. Declaration duly executed by G. Roger Thomas.
3. Petition Under 37 C.F.R. §1.47(a)
4. Documents mailed to Martin Bednar on April 18, 2001
5. Second Request (April 18th letter) to Martin Bednar (sent May 24, 2001)
6. Copy of Undeliverable envelope received from Federal Express
7. Declaration by Legal Representative of Cordell E. Gross in Accordance with C.F.R. §1.42
8. Certification of Appointment of Linda J. Gross as the Executrix of the Estate of Cordell E. Gross, Deceased
9. Certification of Death
10. Declaration duly executed by Linda Gross as the Executrix of the Estate of Cordell E. Gross, Deceased.
11. Amendment and Response to Notice to File Missing Parts of Nonprovisional Application



Sequence Listing (revised)

13. Computer Readable Format for Sequence Listing (revised)
14. Certificate Re: Sequence Listing and computer-readable diskette
15. Formal Drawings (Fig. 1, Fig. 2, Fig. 3, Fig. 4A and Fig. 4B)

The Commissioner is hereby authorized to deduct the appropriate surcharge fee of \$130 associated with this communication or credit any overpayment to Deposit Account No. 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: June 11, 2001

By: 

Richard B. Love

Reg. No. 34,659

Telephone No. (650) 225-5530



09157

PATENT TRADEMARK OFFICE